Does the Addition of Low-Dose Methotrexate to Antithyroidal Drugs Improve Remission Rates in Graves' Disease?

In this prospective, open-label trial, methotrexate (MTX), an oral immunomodulatory drug, added to methimazole was tested against methimazole alone in patients with newly diagnosed Graves' disease (GD), assessing the rate or remission after 18 months of therapy.• After 18 months, low-dose MTX as an adjunct to methimazole led to higher remission rates of GD as compared to methimazole alone.• Low-dose MTX was safe and well tolerated.